Stifel Starts Sutro Biopharma at Buy With $48 Target on ADC Platform Potential
Stifel highlights ADC platform potential, dual-payload pipeline strength, near-term catalysts, and cash runway through 2028.
/ 5 items
#STRO↓
5 Hot Biotech Stocks With Fresh Buy Ratings
Analysts initiate coverage with Buy ratings on Sensei (SNSE), Septerna (SEPN), Kazia (KZIA), NervGen (NGEN), and Sutro (STRO).
Wall Street Upgrades Two Biotech Stocks: STRO Price Target Tripled, ORIC Now a Buy
Wedbush lifts Sutro to $60 on STRO-004 hopes; ORIC upgraded on strong cancer data and big market potential.
Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma
Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target.
Wall Street Goes Bullish on Sutro Biopharma: Two Major Upgrades After Q4 Results
Wells Fargo upgrades to Overweight with $27 PT and H.C. Wainwright raises to Buy with $28 target on strong STRO-004 progress.